Article in Signal transduction and targeted therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
10 authors.
Yuqiao Wang *New Cornerstone Science Laboratory, CAS Key Laboratory of Biomedical Effects of Nanomaterials and Nanosafety and CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology of China, University of Chinese Academy of Sciences, Beijing, China.ORCID http://orcid.org/0000-0003-0733-7987
Hao Zhao *New Cornerstone Science Laboratory, CAS Key Laboratory of Biomedical Effects of Nanomaterials and Nanosafety and CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology of China, University of Chinese Academy of Sciences, Beijing, China. zhaoh@hospital.cqmu.edu.cn.ORCID http://orcid.org/0000-0002-5848-9457
Ke SunChongqing Key Laboratory of Ultrasound Molecular Imaging, the Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Dan DengSchool of Medical Imaging, Changsha Medical University, Changsha, China.
Guanyu LiuNew Cornerstone Science Laboratory, CAS Key Laboratory of Biomedical Effects of Nanomaterials and Nanosafety and CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology of China, University of Chinese Academy of Sciences, Beijing, China.
Lan LiNew Cornerstone Science Laboratory, CAS Key Laboratory of Biomedical Effects of Nanomaterials and Nanosafety and CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology of China, University of Chinese Academy of Sciences, Beijing, China.
Tao LiuNew Cornerstone Science Laboratory, CAS Key Laboratory of Biomedical Effects of Nanomaterials and Nanosafety and CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology of China, University of Chinese Academy of Sciences, Beijing, China.
Lin BaoNew Cornerstone Science Laboratory, CAS Key Laboratory of Biomedical Effects of Nanomaterials and Nanosafety and CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology of China, University of Chinese Academy of Sciences, Beijing, China.ORCID http://orcid.org/0000-0003-1894-0589
Wei XuBeijing Synchrotron Radiation Facility, Institute of High Energy Physics, Beijing, China.
Chunying ChenNew Cornerstone Science Laboratory, CAS Key Laboratory of Biomedical Effects of Nanomaterials and Nanosafety and CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology of China, University of Chinese Academy of Sciences, Beijing, China. chenchy@nanoctr.cn.ORCID http://orcid.org/0000-0002-6027-0315
Funding
China Postdoctoral Science Foundation 2022M720933China Postdoctoral Science Foundation 2022T150151National Natural Science Foundation of China (National Science Foundation of China) 12075273National Natural Science Foundation of China (National Science Foundation of China) 32201099
6 · The paper itself
Abstract
Pyroptosis, which rapidly releases cellular contents through pyroptotic pores, is an ideal method for inducing in situ cancer vaccines, evoking systemic antitumor immunity, and suppressing primary and metastatic tumors. However, the clinical translation of pyroptosis-based therapy is hindered by the inability to spatially control the activation of inert precursors and the inefficient catalytic activity of nanozymes, which often fail to generate sufficient reactive oxygen species for effective treatment. To address this, we designed a conductive coordination nanozyme prodrug, Cu-DHN. Its π-conjugated polyphenol backbone functions as an intrinsic "electron highway," enabling rapid electron shuttling to utilize the entire nanoparticle volume for catalysis, thereby achieving exceptional peroxidase-like activity. Upon systemic administration, Cu-DHN remains inert in circulation but is precisely activated within the tumor microenvironment by a tandem GSH-depletion and H
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Conductive coordination nanozyme prodrugs precisely trigger pyroptosis, cuproptosis and ferroptosis for in situ cancer vaccination. · full record | OpenQuestion